Department of Biochemistry and Molecular Biology II, School of Pharmacy, University of Granada, 18071 Granada, Spain.
Institute of Nutrition and Food Technology "José Mataix", Center of Biomedical Research, University of Granada, Avda. del Conocimiento s/n., 18016 Armilla, Granada, Spain.
Nutrients. 2020 Feb 26;12(3):605. doi: 10.3390/nu12030605.
The importance of gut microbiota in health and disease is being highlighted by numerous research groups worldwide. Atherosclerosis, the leading cause of heart disease and stroke, is responsible for about 50% of all cardiovascular deaths. Recently, gut dysbiosis has been identified as a remarkable factor to be considered in the pathogenesis of cardiovascular diseases (CVDs). In this review, we briefly discuss how external factors such as dietary and physical activity habits influence host-microbiota and atherogenesis, the potential mechanisms of the influence of gut microbiota in host blood pressure and the alterations in the prevalence of those bacterial genera affecting vascular tone and the development of hypertension. We will also be examining the microbiota as a therapeutic target in the prevention of CVDs and the beneficial mechanisms of probiotic administration related to cardiovascular risks. All these new insights might lead to novel analysis and CVD therapeutics based on the microbiota.
肠道微生物群在健康和疾病中的重要性正受到全球众多研究小组的关注。动脉粥样硬化是心脏病和中风的主要原因,约占所有心血管疾病死亡人数的 50%。最近,肠道菌群失调已被确定为心血管疾病(CVD)发病机制中值得考虑的重要因素。在这篇综述中,我们简要讨论了饮食和体育活动等外部因素如何影响宿主-微生物群和动脉粥样硬化的形成,肠道微生物群对宿主血压的影响的潜在机制,以及影响血管张力和高血压发展的那些细菌属的流行率的改变。我们还将研究微生物群作为预防 CVD 的治疗靶点,以及与心血管风险相关的益生菌管理的有益机制。所有这些新的见解可能会导致基于微生物群的新的分析和 CVD 治疗。